Health expenditure accounts for a significant part of overall public spending. In the future, it is expected to increase further in response to demographic trends such as ageing populations (OECD, 2021). Health cost effectiveness is assessed by comparing countries’ improvements in life expectancy at birth (outcome) to their total health expenditure per capita (input). Current health expenditure comprises both public and private health spending; the latter may be particularly high in countries without comprehensive public health schemes, such as the United States. Life expectancy is a broad measure of health-spending effectiveness, as it can also be affected by factors beyond healthcare activities and spending, including life habits, physical environment and behavioural factors. Nonetheless, there is a positive relation between health spending and life expectancy at birth, with diminishing returns to health spending (Figure 11.8).
In countries such as Japan, Korea and Israel, life expectancy is relatively high given health expenditure levels. On the other hand, countries such as Mexico, Latvia and Lithuania have comparatively low life expectancy compared to other countries that spend similar amounts on health. An explanatory factor in Mexico may be comparatively high obesity rates, while substance abuse and self-harm significantly contributed to low life expectancy in both Baltic countries (Stumbrys et al., 2022). The United States has one of the lowest life expectancies (77 years), despite having by far the highest level of health expenditure per capita among OECD countries. Beyond affordability of healthcare, other factors like drug overdoses, firearm-related deaths and mental disorders may help explain this relatively low outcome (Ho, 2022).